Faze Is Newest Swimmer In Pool of Biotechs Targeting Biomolecular Condensates
Significant Cash Injection
Buoyed by an $81m Series A financing round, Faze Medicines joins Dewpoint Therapeutics and Nereid Therapeutics in the race to develop small-molecule drugs targeting biomolecular condensates, an emerging field of cell biology.
